Lactate Clearance in Hospital-acquired Pneumonia
Sponsor
Ankara City Hospital Bilkent (Other)
Overall Status
Completed
CT.gov ID
NCT04826848
Collaborator
(none)
69
1
6
11.5
Study Details
Study Description
Brief Summary
There is no clear consensus on the use of pneumonia severity index (PSI) developed for community-acquired pneumonia in hospital-acquired pneumonia cases. In another aspect, PSI is a relatively difficult scoring system that includes many parameters. This study evaluated whether lactate clearance could be used as a mortality marker instead of PSI in hospital-acquired pneumonia. As a result, lactate clearance was lower in the mortal group and when the diagnostic statistics were evaluated, it was seen that the sensitivity and specificity rates were significantly higher. In conclusion, lactate clearance has been evaluated as a strong predictor of mortality in hospital-acquired pneumonia.
Study Design
Study Type:
Observational
Actual Enrollment
:
69 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The Prognostic Value of Lactate Clearance in Hospital-acquired Pneumonia
Actual Study Start Date
:
Jun 1, 2019
Actual Primary Completion Date
:
Dec 1, 2019
Actual Study Completion Date
:
Dec 1, 2019
Outcome Measures
Primary Outcome Measures
- Mortality [28 day]
28-day mortality
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- 18 and over age, hospital-acquired pneumonia, emergency department admissions
Exclusion Criteria:
- Patients who are pregnant or lactating, under 18 years of age, in the healthcare-associated pneumonia group, had mechanical ventilation at the last hospitalization, whose lactate level could not be studied for any reason at admission and 6th hour, had missing data used in pneumonia severity index calculation and/or who did not accept to participate in the study
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Ankara Yıldırım Beyazıt University, School of Medicine, Department of Emergency Medicine | Ankara | Çankaya | Turkey | 06800 |
Sponsors and Collaborators
- Ankara City Hospital Bilkent
Investigators
- Principal Investigator: Alp Şener, MD, Ankara Yıldırım Beyazıt University Faculty of Medicine
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Ankara City Hospital Bilkent
ClinicalTrials.gov Identifier:
NCT04826848
Other Study ID Numbers:
- LC-HAP
First Posted:
Apr 1, 2021
Last Update Posted:
May 26, 2021
Last Verified:
Mar 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: